SLS
Sellas Life Sciences Group Inc
11.60$
-3.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 36.1% | 65.3% | 57.0% | 39.0% | 34.5% | 49.6% | 80.2% | 87.2% | 84.8% | 51.0% | 84.0% | 96.0% | |
| 29.4% | 36.2% | 27.5% | 6.9% | 31.6% | 43.8% | 76.7% | 81.2% | 81.8% | 40.7% | 71.5% | 91.8% | |
| 29.4% | 36.2% | 27.5% | 6.9% | 31.6% | 43.8% | 76.7% | 81.2% | 81.8% | 40.7% | 71.5% | 91.8% | |
| 2.3% | 26.4% | – | – | – | 1.9% | 2.4% | – | – | – | – | – | |
| 0.8% | -23.7% | 0.0% | 0.0% | – | 3.4% | 1.0% | – | – | – | – | – | |
| 0.4% | 0.4% | 0.3% | 0.0% | – | 1.3% | 1.9% | 2.7% | 4.2% | – | – | – | |
| 7.5% | 7.2% | 9.0% | 5.7% | 11.3% | 11.5% | 4.2% | 7.2% | 9.1% | 30.8% | 9.8% | 2.4% | |
| 55.6% | 26.9% | 33.6% | 52.5% | 50.3% | 34.3% | 12.4% | – | – | – | – | – | |
| 54.0% | 83.5% | 56.5% | 93.8% | 69.0% | 63.3% | 39.3% | 23.0% | 76.8% | 228.3% | 51.3% | 9.5% | |
| 33.8% | 69.5% | 46.2% | 73.3% | 35.3% | 31.9% | 26.8% | 18.9% | 74.1% | 220.9% | 48.9% | 9.0% | |
| 4.9% | 5.8% | 24.9% | 25.0% | – | 1.3% | 0.4% | 0.7% | 1.8% | 7.2% | 2.8% | 0.7% | |
| 2.8% | 1.9% | 1.3% | 34.9% | 22.2% | 23.5% | 10.1% | 8.1% | 16.0% | 90.7% | 18.0% | 3.8% | |
| 5.6% | 13.3% | 8.6% | 7.8% | – | – | – | – | – | – | – | – | |
| 46.0% | 16.5% | 43.5% | 6.2% | 31.0% | 36.7% | 60.7% | 77.0% | 23.2% | -128.3% | 48.7% | 90.5% | |
| -267.7% | -340.1% | -460.3% | -161.6% | -483.9% | -609.0% | -256.0% | -524.5% | -859.0% | -3,493.2% | -1,276.9% | -351.0% | |
| 0.0% | 0.0% | 0.5% | 0.1% | 1.5% | 15.4% | 17.3% | 58.6% | 92.6% | 446.6% | 315.0% | 139.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.